Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta® in healthy subjects: A randomized, double‐blind trial

• Auteurs principaux: Chris Wynne (Auteur), Christian Schwabe (Auteur), Emmanuelle Vincent (Auteur), Armin Schueler (Auteur), Janka Ryding (Auteur), Martin Ullmann (Auteur), Vishal Ghori (Auteur), Radmila Kanceva (Auteur), Michael Stahl (Auteur)
• Format: Livre
• Publié: Wiley, 2020-04-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Abstract MSB11455 is a proposed biosimilar to the currently licensed reference pegfilgrastim (Neulasta®). This study was designed primarily to compare the immunogenicity of MSB11455 and Neulasta®. As secondary objectives, the safety and tolerability of MSB11455 and Neulasta® were also compared. Heal...